OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: Weill Medical College of Cornell University

8 Projects | 6 Researchers | $5,151,682 Invested

2020

Weill Medical College of Cornell University

Anna Orr, PhD

Lead Optimization of Novel Site-Selective Blockers of Mitochondrial Complex III ROS as FTD Therapeutics

  • Funding Amount: $135,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Mitochondria/Metabolic Function
  • Status: Closed

2018

Weill Medical College of Cornell University

Richard Isaacson, MD

Evaluating the effectiveness of CognitiveVitality.org on learning about brain health: a randomized, crossover study in the lay public and healthcare professionals

  • Funding Amount: $100,000
  • Organization Type: Academic/Nonprofit
  • Program: Prevention
  • Target: Other
  • Status: Closed

2017

Weill Medical College of Cornell University

Ronald Crystal, MD

Phase I study of an AAVrh.10-mediated Apolipoprotein E2 Gene Delivery to the CNS for the treatment of Alzheimer's Disease in E4 Homozygotes .

  • Funding Amount: $3,006,472
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: zzAPOE
  • Status: Active

2014

Weill Medical College of Cornell University

Ronald Crystal, MD

Translation to the Clinic of AAVrh.10-mediated Delivery to the CNS of the Apolipoprotein E2 Gene for Treatment of Alzheimer's Disease

  • Funding Amount: $1,000,000
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: zzAPOE
  • Status: Closed

2013

Weill Medical College of Cornell University

Steven Paul, MD

Gene Delivery of Apolipoprotein E2 as a Treatment for Alzheimer's Disease

  • Funding Amount: $500,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2011

Weill Medical College of Cornell University

Steven Paul, MD

Gene delivery of apolipoprotein E2 as a treatment for Alzheimer's disease.

  • Funding Amount: $250,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2006

Weill Medical College of Cornell University

Gary Gibson, PhD

Tests of therapies aimed at mitochondrial deficits in neurodegenerative diseases

  • Funding Amount: $80,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2002

Weill Medical College of Cornell University

Marc Weksler, PhD

Human anti-A Beta Antibodies for the Treatment of Alzheimer's Disease

  • Funding Amount: $80,210
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed